Refractory B-Cell Non-Hodgkin Lymphoma
Showing 1 - 25 of 32
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia Trial
Not yet recruiting
- Recurrent B Acute Lymphoblastic Leukemia
- +5 more
- Interferon Beta-1A
- +10 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 6, 2023
High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma, Recurrent B-Cell Non-Hodgkin
Not yet recruiting
- High Grade B-Cell Non-Hodgkin's Lymphoma
- +3 more
- Anti-CD19-CAR CMV-specific T-lymphocytes
- +9 more
-
Duarte, CaliforniaCity of Hope Medical Center
Apr 5, 2023
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Venetoclax
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023
Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker
Suspended
- Recurrent Aggressive Non-Hodgkin Lymphoma
- +5 more
- Laboratory Biomarker Analysis
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 12, 2023
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial
Active, not recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Carboplatin
- +5 more
-
Jacksonville, Florida
- +11 more
Jan 12, 2023
ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United
Active, not recruiting
- ALK-Positive Large B-Cell Lymphoma
- +34 more
- Nivolumab
- Varlilumab
-
Phoenix, Arizona
- +32 more
Jan 3, 2023
CB-Long-Term Safety Study (CB-LTSS)
Enrolling by invitation
- Lymphoma, Non-Hodgkin
- +7 more
- Allogeneic CAR-T therapy
-
Irvine, California
- +3 more
Nov 18, 2022
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston
Not yet recruiting
- Refractory Aggressive B-cell Lymphomas
- +12 more
- ACALABRUTINIB
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 13, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +13 more
- Polatuzumab Vedotin
- +3 more
-
Scottsdale, Arizona
- +11 more
Aug 23, 2022
Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL Trial in Houston
Recruiting
- Refractory B-Cell Non-Hodgkin Lymphoma
- +4 more
- CD19.CAR-aNKT cells
- +2 more
-
Houston, Texas
- +1 more
Aug 19, 2022
Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in United States (CB-010,
Recruiting
- Lymphoma, Non-Hodgkin
- +6 more
- CB-010
- +2 more
-
Scottsdale, Arizona
- +7 more
Aug 19, 2022
Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in
Active, not recruiting
- Hematopoietic Cell Transplantation Recipient
- +3 more
- Allogeneic Bone Marrow Transplantation
- +10 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in
Recruiting
- Recurrent Anaplastic Large Cell Lymphoma
- +9 more
- Anti-CD30/CD16A Monoclonal Antibody AFM13
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in Worldwide
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- +2 more
- Loncastuximab Tesirine
- +4 more
-
Pembroke Pines, Florida
- +19 more
Jul 22, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jul 14, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +20 more
- Chimeric Antigen Receptor T-Cell Therapy
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 11, 2022
Post-Transplant Lymphoproliferative Disorder, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Seattle
Not yet recruiting
- Post-Transplant Lymphoproliferative Disorder
- +10 more
- Loncastuximab Tesirine
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 6, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Hodgkin Lymphoma Trial in New York (Decitabine and
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +5 more
- Decitabine and Cedazuridine
- Nivolumab
-
New York, New YorkNY011 Laura and Isaac Perlmutter Cancer Center at NYU Langone
Jul 8, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Advanced Pancreatic Carcinoma Trial in New Haven (BET Bromodomain Inhibitor
Recruiting
- Advanced Lymphoma
- +13 more
- BET Bromodomain Inhibitor ZEN-3694
- +2 more
-
New Haven, ConnecticutYale University Cancer Center LAO
Jun 29, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +23 more
- Lenalidomide
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 23, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of
Active, not recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +22 more
- Ibrutinib
- +3 more
-
Scottsdale, Arizona
- +1 more
Aug 10, 2021
Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in France (Selicrelumab, Atezolizumab)
Terminated
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
-
Créteil, France
- +4 more
Jul 23, 2021
Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Leukemia Trial in Chengdu (Modified anti-CD19 CAR T cells)
Active, not recruiting
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Leukemia
- Modified anti-CD19 CAR T cells
-
Chengdu, Sichuan, ChinaSichuan University
Mar 17, 2021
Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai, Hangzhou (CAR-CD19 T Cells)
Recruiting
- Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed B-cell Non-Hodgkin Lymphoma
- CAR-CD19 T Cells
-
Shanghai, Shanghai, China
- +1 more
Oct 7, 2020